-transparent.png){kind=logo}
20 psychotic - predominantly schizophrenic - patients underwent treatment with the new butyrophenone derivative bromperidol for a period of 4 weeks; the drug was administered in the form of 1 mg tablets. The daily dose (initial dose: 1 mg; mean dose at the end of the trial: 4.47 mg) was always administered in one single dose. 19 patients finished the trial, and in 18 cases the therapeutic result was considered very good to good. These results were confirmed by statistical analysis. Nine patients exhibited mild to moderate extrapyramidal concomitant symptoms; no other side effects were observed. The results of detailed laboratory tests and evaluations of various quantitative and qualitative tolerability parameters were not indicative of toxic effects. The therapeutic value of this new substance will be demonstrated by a double-blind study.
W Pöldinger, and
E Bures, and
H Haage
January 1982,
Psychopharmacology,
W Pöldinger, and
E Bures, and
H Haage
January 1985,
Psychopharmacology bulletin,
W Pöldinger, and
E Bures, and
H Haage
January 1968,
Acta psychiatrica Scandinavica. Supplementum,
W Pöldinger, and
E Bures, and
H Haage
July 1969,
Current therapeutic research, clinical and experimental,
W Pöldinger, and
E Bures, and
H Haage
November 1963,
Schweizerische medizinische Wochenschrift,
W Pöldinger, and
E Bures, and
H Haage
January 1966,
Psychopharmacologia,
W Pöldinger, and
E Bures, and
H Haage
April 1964,
Acta neurologica et psychiatrica Belgica,
W Pöldinger, and
E Bures, and
H Haage
December 1964,
Hospital (Rio de Janeiro, Brazil),
W Pöldinger, and
E Bures, and
H Haage
February 1967,
Nordisk medicin,
W Pöldinger, and
E Bures, and
H Haage
November 1963,
The American journal of psychiatry,
